Manufacturing Chemist Manufacturing Chemist
  • Home
  • Ingredients
  • Packaging
  • Manufacturing
  • Finance
  • Events
  • Directory
  • Regulatory
  • Drug Delivery
  • Research & Development
  • Analysis

Samsung Biologics

www.samsungbiologics.com

300 Songdo Bio Way
Yeonsu-gu
Incheon
21987
Korea (South)

+82 32 455 3114

Activities

Pharmaceutical

Related Companies

  • Rentschler Biopharma SE
  • 3P innovation

Related Content

GreenLight and Samsung complete first commercial-scale engineering run for mRNA COVID-19 vaccine
GreenLight and Samsung complete first commercial-scale engineering run for mRNA COVID-19 vaccine
Navigating the maelstrom of M&A activity: what do CDMOs do next?
Navigating the maelstrom of M&A activity: what do CDMOs do next?
Samsung Biologics completes acquisition of Samsung Bioepis
Samsung Biologics completes acquisition of Samsung Bioepis
Samsung Biologics acquires full ownership of Biogen joint venture
Samsung Biologics acquires full ownership of Biogen joint venture
Samsung Biologics to manufacture AstraZeneca COVID therapy
Samsung Biologics to manufacture AstraZeneca COVID therapy
GreenLight Biosciences and Samsung Biologics announce RNA collaboration
GreenLight Biosciences and Samsung Biologics announce RNA collaboration
Driving biotherapeutic development with advanced molecule characterisation
Driving biotherapeutic development with advanced molecule characterisation
Samsung Biologics to provide CDMO service for Enzolytics mAb therapies
Samsung Biologics to provide CDMO service for Enzolytics mAb therapies
Samsung Biologics to join Frontier 1.5D climate initiative
Samsung Biologics to join Frontier 1.5D climate initiative
Samsung Biologics to provide end-to-end CDMO service for Kineta
Samsung Biologics to provide end-to-end CDMO service for Kineta
Samsung Biologics to support Kahr Medical immunotherapy
Samsung Biologics to support Kahr Medical immunotherapy
Moderna and Samsung Biologics announce manufacturing agreement
Moderna and Samsung Biologics announce manufacturing agreement
The MC roundtable: how CDMOs are responding to pharma’s top priorities in 2021 (part III)
The MC roundtable: how CDMOs are responding to pharma’s top priorities in 2021 (part III)
The MC roundtable: how CDMOs are responding to pharma’s top priorities in 2021 (part II)
The MC roundtable: how CDMOs are responding to pharma’s top priorities in 2021 (part II)
The MC roundtable: how CDMOs are responding to pharma’s top priorities in 2021 (part I)
The MC roundtable: how CDMOs are responding to pharma’s top priorities in 2021 (part I)
  • Advertise Subscribe
  • Terms & Conditions
  • Privacy Policy
  • Contact us at info@hpcimedia.com
Twitter LinkedIn RSS newsfeed
© HPCi Media Limited | Registered in England No. 6716035 | VAT GB 939828072 | a Claverley Group company